EGFR and non-small cell lung carcinoma: In conclusion, NSCLC patients harboring the A763_Y764insFQEA and D770delinsGY ex20ins variants of EGFR display a favorable response to currently approved EGFR TKIs, which should be classified according to the ex20ins variants for more effective therapeutic responses.